180 related articles for article (PubMed ID: 1357812)
1. Proliferating cell nuclear antigen in breast lesions: correlation of c-erbB-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer.
Shrestha P; Yamada K; Wada T; Maeda S; Watatani M; Yasutomi M; Takagi H; Mori M
Virchows Arch A Pathol Anat Histopathol; 1992; 421(3):193-202. PubMed ID: 1357812
[TBL] [Abstract][Full Text] [Related]
2. Expression of proliferating cell nuclear antigen (PC10), p53 protein and c-erbB-2 in renal adenocarcinoma.
Lipponen P; Eskelinen M; Hietala K; Syrjänen K; Gambetta RA
Int J Cancer; 1994 Apr; 57(2):275-80. PubMed ID: 7908898
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of the combined assessment of proliferating cell nuclear antigen immunostaining and nuclear DNA content in invasive human mammary carcinomas.
Schimmelpenning H; Eriksson ET; Franzén B; Zetterberg A; Auer GU
Virchows Arch A Pathol Anat Histopathol; 1993; 423(4):273-9. PubMed ID: 7901939
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical localization of cathepsin D, proliferating cell nuclear antigen and epidermal growth factor receptor in human breast carcinoma analysed by computer image analyser: correlation with histological grade and metastatic behaviour.
Okamura K; Kobayashi I; Matsuo K; Kiyoshima T; Yamamoto K; Miyoshi A; Sakai H
Histopathology; 1997 Dec; 31(6):540-8. PubMed ID: 9447385
[TBL] [Abstract][Full Text] [Related]
5. C-erbB-2 overexpression in primary breast cancer: independent prognostic factor in patients at high risk.
Schönborn I; Zschiesche W; Spitzer E; Minguillon C; Möhner M; Ebeling K; Grosse R
Breast Cancer Res Treat; 1994; 29(3):287-95. PubMed ID: 7914107
[TBL] [Abstract][Full Text] [Related]
6. Receptor status, proliferating activity, and c-erbB2 oncoprotein. An immunocytochemical evaluation in breast cancer.
Campani D; Sarnelli R; Fontanini G; Martini L; Cecchetti D; De Luca F; Squartini F
Ann N Y Acad Sci; 1993 Nov; 698():167-73. PubMed ID: 7904137
[No Abstract] [Full Text] [Related]
7. Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions. With special reference to their prognostic significance in carcinoma.
Tauchi K; Hori S; Itoh H; Osamura RY; Tokuda Y; Tajima T
Virchows Arch A Pathol Anat Histopathol; 1989; 416(1):65-73. PubMed ID: 2573192
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical studies on oncogene products (EGF-R, c-erbB-2) and growth factors (EGF, TGF-alpha) in human breast cancer: their relationship to oestrogen receptor status, histological grade, mitotic index and nodal status.
Umekita Y; Enokizono N; Sagara Y; Kuriwaki K; Takasaki T; Yoshida A; Yoshida H
Virchows Arch A Pathol Anat Histopathol; 1992; 420(4):345-51. PubMed ID: 1348890
[TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ
Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782
[TBL] [Abstract][Full Text] [Related]
10. Significance of immunohistochemical c-erbB-2 product localization pattern for prognosis of primary human breast cancer.
Zschiesche W; Schönborn I; Minguillon C; Spitzer E
Cancer Lett; 1994 Jun; 81(1):89-94. PubMed ID: 7912648
[TBL] [Abstract][Full Text] [Related]
11. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators.
Travis A; Pinder SE; Robertson JF; Bell JA; Wencyk P; Gullick WJ; Nicholson RI; Poller DN; Blamey RW; Elston CW; Ellis IO
Br J Cancer; 1996 Jul; 74(2):229-33. PubMed ID: 8688326
[TBL] [Abstract][Full Text] [Related]
12. Determination of c-erbB-2 protein in primary breast cancer tissue extract using an enzyme immunoassay.
Watanabe T; Fukutomi T; Tsuda H; Adachi I; Nanasawa T; Yamamoto H; Abe K
Jpn J Cancer Res; 1993 Dec; 84(12):1279-86. PubMed ID: 7904987
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients.
Osaki A; Toi M; Yamada H; Kawami H; Kuroi K; Toge T
Am J Surg; 1992 Oct; 164(4):323-6. PubMed ID: 1357997
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of proliferation associated nucleolar antigen P120 in human breast carcinoma.
Freeman JW; McGrath P; Bondada V; Selliah N; Ownby H; Maloney T; Busch RK; Busch H
Cancer Res; 1991 Apr; 51(8):1973-8. PubMed ID: 1672621
[TBL] [Abstract][Full Text] [Related]
15. Relationship of epidermal growth factor receptor (EGFR), proliferating cell nuclear antigen (PCNA) and vimentin expression and various prognostic factors in breast cancer patients.
Koutselini H; Markopoulos C; Lambropoulou S; Gogas H; Kandaraki C; Gogas J
Cytopathology; 1995 Feb; 6(1):14-21. PubMed ID: 7734697
[TBL] [Abstract][Full Text] [Related]
16. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy.
Nicholson RI; McClelland RA; Gee JM; Manning DL; Cannon P; Robertson JF; Ellis IO; Blamey RW
Breast Cancer Res Treat; 1994 Jan; 29(1):117-25. PubMed ID: 7912565
[TBL] [Abstract][Full Text] [Related]
18. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
[TBL] [Abstract][Full Text] [Related]
19. Poor prognostic value of proliferating cell nuclear antigen labelling index in breast carcinoma.
Thomas M; Noguchi M; Kitagawa H; Kinoshita K; Miyazaki I
J Clin Pathol; 1993 Jun; 46(6):525-8. PubMed ID: 8101192
[TBL] [Abstract][Full Text] [Related]
20. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity.
Nicholson RI; McClelland RA; Finlay P; Eaton CL; Gullick WJ; Dixon AR; Robertson JF; Ellis IO; Blamey RW
Eur J Cancer; 1993; 29A(7):1018-23. PubMed ID: 8098946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
